A PYMNTS Company

US: Senate urges FTC to launch antitrust probe of Mylan

By  |  November 8, 2016

The US Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan broke the law by preventing schools from purchasing competing allergy treatments.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The bipartisan request to the Federal Trade Commission by Senate Judiciary Chairman Charles Grassley and Ranking Member Patrick Leahy comes just a few weeks before the committee is slated to convene a hearing to scrutinize a pending $465 million settlement that Mylan has said will resolve claims it underpaid rebates to state and federal Medicaid programs.

    “Due to the dramatic increase of the price of drugs across the board, the FTC should be vigilant in its scrutiny of this market,” the lawmakers wrote.

    In a statement emailed to Reuters, a Mylan spokeswoman defended the company’s ‘EpiPen4Schools’ program, saying it has no purchase requirement for schools to participate and that it offers schools four free EpiPens per calendar year also without purchase restrictions.

    Previously, schools that wished to purchase additional EpiPens could do so in some cases with a discount and a “limited purchase restriction,” but no such restriction remains in place today, she added.

    Full Content: CNBC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.